Charles Schwab Investment Management Inc. Has $54.87 Million Stake in ICU Medical, Inc. (NASDAQ:ICUI)

Charles Schwab Investment Management Inc. lifted its stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 10.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 301,107 shares of the medical instruments supplier's stock after acquiring an additional 27,927 shares during the period. Charles Schwab Investment Management Inc. owned 1.23% of ICU Medical worth $54,868,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ICUI. Intech Investment Management LLC acquired a new position in shares of ICU Medical during the 3rd quarter worth about $815,000. LMR Partners LLP bought a new stake in ICU Medical in the 3rd quarter valued at $3,884,000. Swiss National Bank boosted its holdings in ICU Medical by 5.6% in the 3rd quarter. Swiss National Bank now owns 45,219 shares of the medical instruments supplier's stock valued at $8,240,000 after purchasing an additional 2,400 shares during the period. Thrivent Financial for Lutherans increased its holdings in shares of ICU Medical by 12.9% during the 3rd quarter. Thrivent Financial for Lutherans now owns 19,181 shares of the medical instruments supplier's stock worth $3,495,000 after purchasing an additional 2,190 shares during the period. Finally, Mutual of America Capital Management LLC increased its holdings in shares of ICU Medical by 9.2% during the 3rd quarter. Mutual of America Capital Management LLC now owns 3,673 shares of the medical instruments supplier's stock worth $669,000 after purchasing an additional 308 shares during the period. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Price Performance

Shares of NASDAQ:ICUI traded up $4.21 on Friday, hitting $163.96. The stock had a trading volume of 159,148 shares, compared to its average volume of 261,729. The firm's 50 day moving average price is $174.60 and its 200-day moving average price is $147.37. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. ICU Medical, Inc. has a twelve month low of $83.26 and a twelve month high of $196.26. The company has a market capitalization of $4.01 billion, a price-to-earnings ratio of -35.88 and a beta of 0.66.

Insider Buying and Selling at ICU Medical

In other news, Director David C. Greenberg sold 972 shares of the firm's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total value of $153,682.92. Following the completion of the sale, the director now directly owns 5,037 shares in the company, valued at approximately $796,400.07. This trade represents a 16.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Vivek Jain sold 12,000 shares of the company's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $18,665,666.78. This trade represents a 10.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 40,364 shares of company stock worth $6,876,478 over the last ninety days. Corporate insiders own 6.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ICUI shares. KeyCorp lifted their target price on ICU Medical from $198.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 13th. Raymond James raised their target price on ICU Medical from $158.00 to $190.00 and gave the stock an "outperform" rating in a research report on Thursday, September 12th. Jefferies Financial Group began coverage on shares of ICU Medical in a report on Monday, October 14th. They issued a "hold" rating and a $183.00 price target on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of ICU Medical in a report on Wednesday, November 13th. Finally, StockNews.com raised shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $173.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.